Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac®) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China

[1]  F. Tian,et al.  Safety and efficacy of COVID‐19 vaccines in children and adolescents: A systematic review of randomized controlled trials , 2022, Journal of medical virology.

[2]  J. Hu,et al.  Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study , 2022, medRxiv.

[3]  Jue Liu,et al.  Effectiveness and Safety of SARS-CoV-2 Vaccines among Children and Adolescents: A Systematic Review and Meta-Analysis , 2022, Vaccines.

[4]  Jun Li,et al.  The Impact of Age Difference on the Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis , 2021, Frontiers in Immunology.

[5]  Jue Liu,et al.  Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis , 2021, Infectious Diseases of Poverty.

[6]  A. Sette,et al.  Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Xinghui Chen,et al.  Evaluation of the safety profile of COVID-19 vaccines: a rapid review , 2021, BMC Medicine.

[8]  A. Reiner-Benaim,et al.  Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer , 2021, Annals of Oncology.

[9]  E. Undurraga,et al.  Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile , 2021, The New England journal of medicine.

[10]  H. Zou,et al.  Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials , 2021, Infectious Diseases of Poverty.

[11]  A. Yılmaz,et al.  Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey , 2021, The Lancet.

[12]  N. Regev,et al.  Short‐term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID‐19 vaccine , 2021, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[13]  Changgui Li,et al.  Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial , 2021, The Lancet Infectious Diseases.

[14]  C. Olson,et al.  Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons , 2021, The New England journal of medicine.

[15]  X. W. Wang,et al.  [Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use]. , 2021, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[16]  D. Segev,et al.  Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients , 2021, Transplantation.

[17]  D. Segev,et al.  Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases , 2021, Annals of the Rheumatic Diseases.

[18]  W. Yin,et al.  Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial , 2021, Lancet. Infectious Diseases (Print).